Dexcom Doubles Down On Jonas Branding To Hail G7 Launch
Executive Summary
Dexcom is commemorating the US launch of its G7 continuous glucose monitor with an expensive ad spot during the Super Bowl.
You may also be interested in...
Minute Insight: CMS Expands Medicare Coverage For CGM
The new policy expands coverage to more Medicare beneficiaries using insulin to treat diabetes, as well as people who need help managing hypoglycemia, and removes the prior requirement of multiple daily insulin injections.
News We’re Watching – Medicare Covers Dexcom CGM; New Mpox EUA; $106M Patent Verdict Against Medtronic
Medicare announced coverage for the Dexcom G7 continuous glucose monitor, as well as a breast cancer indication for Natera Inc.’s Signatera; the FDA authorized a new monkeypox test; the FDA issued a warning letter to a Texas masks firm; and a new report says NIST labs are failing behind.
Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.